AHR and asthma: In a further comparison to FF, the leading clinical compound for asthma treatment, both VSGC12 and FF delivered a maximal repression activity to strongly suppress the AHR to the basal level at the dose of 1 mg kg–1, largely surpassing DEX (Figure 3a).